C-MER Eye Care (03309) Reports Interim Results with Shareholders' Profit of HK$29.76 Million, Up 100.9% Year-on-Year

C-MER Medical (03309) announced its interim results for the six months ended June 30, 2023. The group's revenue was HKD 950 million, representing a year-on-year increase of 7.8%; profit attributable to shareholders was HKD 29.758 million, marking a year-on-year increase of 100.9%; earnings per share were 2.36 HK cents.

The announcement stated that the revenue growth was mainly driven by the following factors: (i) Revenue from ophthalmology services increased by 23.4% from HKD 511 million in the same period last year to HKD 630 million in the first half of 2023, primarily due to an increase in the number of surgeries performed by the company in Hong Kong and mainland China; (ii) Revenue from dental services surged from HKD 65.3 million in the same period last year to HKD 193 million in the first half of 2023, representing a 194.9% growth, mainly attributed to the resumption of border crossings between Hong Kong and Shenzhen, which significantly boosted the business volume of Shenzhen Aikangjian, but this growth was partially offset by the following factor: (iii) Revenue from the sale of medical consumables decreased from HKD 221 million in the same period last year to HKD 19.4 million in the first half of 2023.